$BNTC
Benitec Biopharma Inc.

2024 Q3 Form 10-K Financial Statement

#000119312524226968 Filed on September 26, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2024
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue $0.00 $0.00 -$108.0K
YoY Change -100.0%
Gross Profit $0.00 $0.00 $108.0K
YoY Change -100.0% 35.0%
Gross Profit Margin
Selling, General & Admin $2.206M $2.036M $6.989M
YoY Change 42.23% 48.61% 9.55%
% of Gross Profit 6471.3%
Research & Development $3.585M $3.512M $15.61M
YoY Change -19.06% 10.09% 22.19%
% of Gross Profit 14452.78%
Depreciation & Amortization $25.00K $26.00K $87.00K
YoY Change 31.58% -36.03%
% of Gross Profit 80.56%
Operating Expenses $5.791M $5.548M $22.49M
YoY Change -1.41% 21.67% 17.4%
Operating Profit -$5.791M -$5.548M -$22.49M
YoY Change -1.41% 17.87%
Interest Expense $604.0K $982.0K $904.0K
YoY Change -10166.67% -3373.33% -2839.39%
% of Operating Profit
Other Income/Expense, Net $732.0K -$154.0K $739.0K
YoY Change -1015.0% 92.5% -253.64%
Pretax Income -$5.059M -$4.720M -$21.04M
YoY Change -15.03% 1.29% 10.99%
Income Tax
% Of Pretax Income
Net Earnings -$5.100M -$5.339M -$21.75M
YoY Change -15.0% 14.57% 11.19%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48 -$5.51
Diluted Earnings Per Share -$0.48 -$0.60 -$5.51
COMMON SHARES
Basic Shares Outstanding 10.56M 9.367M 4.060M
Diluted Shares Outstanding 10.64M 4.060M

Balance Sheet

Concept 2024 Q3 2024 Q2 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.84M $50.87M
YoY Change 162.3% 1951.05%
Cash & Equivalents $67.80M $50.90M
Short-Term Investments
Other Short-Term Assets $426.0K $516.0K
YoY Change -11.62% -56.42%
Inventory
Prepaid Expenses $481.0K $577.0K
Receivables $4.000K $229.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $68.34M $51.67M
YoY Change 158.73% 1285.73%
LONG-TERM ASSETS
Property, Plant & Equipment $154.0K $179.0K
YoY Change 126.47% 105.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $56.00K $62.00K
YoY Change -34.12% -36.08%
Total Long-Term Assets $439.0K $536.0K
YoY Change -31.51% -27.07%
TOTAL ASSETS
Total Short-Term Assets $68.34M $51.67M
Total Long-Term Assets $439.0K $536.0K
Total Assets $68.77M $52.21M
YoY Change 154.22% 1069.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $903.0K $1.351M
YoY Change -40.9% 18.51%
Accrued Expenses $3.591M $3.435M
YoY Change 21.07% 24.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.553M $4.924M
YoY Change 0.42% 23.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $41.00K $38.00K
YoY Change -80.57% -86.43%
Total Long-Term Liabilities $41.00K $38.00K
YoY Change -80.57% -86.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.553M $4.924M
Total Long-Term Liabilities $41.00K $38.00K
Total Liabilities $4.594M $4.962M
YoY Change -3.18% 16.42%
SHAREHOLDERS EQUITY
Retained Earnings -$195.3M -$190.3M
YoY Change 12.35% 13.32%
Common Stock $260.5M $238.4M
YoY Change 32.28% 41.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.18M $47.25M
YoY Change
Total Liabilities & Shareholders Equity $68.77M $52.21M
YoY Change 154.22% 1069.58%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2024
OPERATING ACTIVITIES
Net Income -$5.100M -$5.339M -$21.75M
YoY Change -15.0% 14.57% 11.19%
Depreciation, Depletion And Amortization $25.00K $26.00K $87.00K
YoY Change 31.58% -36.03%
Cash From Operating Activities -$4.600M -$3.293M -$19.40M
YoY Change 0.0% -19.49% 7.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $179.0K
YoY Change 17800.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$179.0K
YoY Change 17800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.66M 40.07M 68.03M
YoY Change -22.44% 324.78%
NET CHANGE
Cash From Operating Activities -4.600M -3.293M -19.40M
Cash From Investing Activities 0.000 0.000 -179.0K
Cash From Financing Activities 21.66M 40.07M 68.03M
Net Change In Cash 16.98M 36.78M 48.44M
YoY Change -27.41% -999.22% -3154.16%
FREE CASH FLOW
Cash From Operating Activities -$4.600M -$3.293M -$19.40M
Capital Expenditures $0.00 $179.0K
Free Cash Flow -$3.293M -$19.58M
YoY Change -19.49% 8.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4620206
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001808898
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
001-39267
CY2024 dei Entity Registrant Name
EntityRegistrantName
Benitec Biopharma Inc.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
3940 Trust Way
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
CY2024 dei City Area Code
CityAreaCode
510
CY2024 dei Local Phone Number
LocalPhoneNumber
780-0819
CY2024 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
CY2024 dei Trading Symbol
TradingSymbol
BNTC
CY2024 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Public Float
EntityPublicFloat
8373562
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10555728
CY2024 dei Auditor Firm
AuditorFirmId
23
CY2024 dei Auditor Name
AuditorName
Baker Tilly US, LLP
CY2024 dei Auditor Location
AuditorLocation
San Jose, California
CY2024Q2 us-gaap Due From Banks
DueFromBanks
50866000
CY2023Q2 us-gaap Due From Banks
DueFromBanks
2477000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2024Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
229000
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
55000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
516000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1184000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
51674000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
3729000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
179000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87000
CY2024Q2 us-gaap Deposit Assets
DepositAssets
25000
CY2023Q2 us-gaap Deposit Assets
DepositAssets
25000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
62000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
97000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
270000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
526000
CY2024Q2 us-gaap Assets
Assets
52210000
CY2023Q2 us-gaap Assets
Assets
4464000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4165000
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3231000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
475000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
472000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
284000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4924000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3978000
CY2024Q2 bntc Non Accrued Accrued Employee Benefits Non Current
NonAccruedAccruedEmployeeBenefitsNonCurrent
38000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000
CY2024Q2 us-gaap Liabilities
Liabilities
4962000
CY2023Q2 us-gaap Liabilities
Liabilities
4262000
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10086119
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10086119
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1671485
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1671485
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
238398000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168921000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-190259000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167889000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-892000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-830000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
47248000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
202000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52210000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4464000
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
75000
CY2024 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
-108000
CY2023 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
0
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15609000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12774000
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6989000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6382000
CY2024 us-gaap Operating Expenses
OperatingExpenses
22490000
CY2023 us-gaap Operating Expenses
OperatingExpenses
19156000
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-22490000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-19081000
CY2024 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
40000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-415000
CY2024 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
904000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-33000
CY2024 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-204000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
CY2024 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1000
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3000
CY2024 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
739000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-481000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21751000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2024 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-62000
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
415000
CY2024 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-62000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
415000
CY2024 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21813000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19147000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21751000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2024 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
619000
CY2023 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
0
CY2024 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22370000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19562000
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.51
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.51
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.12
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.12
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4060182
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4060182
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1385818
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1385818
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2882000
CY2023 bntc Issuance And Exercise Of Prefunded And Common Warrants Net Of Transaction Costs
IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
16015000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
452000
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
415000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
202000
CY2024 bntc Issuance And Exercise Of Prefunded And Common Warrants Net Of Transaction Costs
IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
27919000
CY2024 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
190000
CY2024 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2848000
CY2024 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
830000
CY2024 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-62000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21751000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
47248000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21751000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2024 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
87000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
136000
CY2024 bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
256000
CY2023 bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
245000
CY2024 bntc Unrealized Gain Loss On Investment
UnrealizedGainLossOnInvestment
-1000
CY2023 bntc Unrealized Gain Loss On Investment
UnrealizedGainLossOnInvestment
-3000
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
830000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
452000
CY2024 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
176000
CY2023 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
50000
CY2024 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-645000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
414000
CY2024 bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
941000
CY2023 bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
1357000
CY2024 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
39000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
73000
CY2024 bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-275000
CY2023 bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-252000
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19403000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18012000
CY2024 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
179000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-179000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1000
CY2024 bntc Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants
ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants
73921000
CY2023 bntc Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants
ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants
17884000
CY2024 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5892000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1869000
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68029000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16015000
CY2024 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
412000
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
48439000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1586000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2490000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4076000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50929000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2490000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50866000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2477000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50929000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2490000
CY2024 bntc Warrant Antidilution Provision
WarrantAntidilutionProvision
619000
CY2024 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-11-22
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On July 26, 2023, the Company effected a 1-for-17 reverse stock split (the “Reverse Stock Split”) of its common stock. In accordance with the Reverse Stock Split, 17 pre-split shares of the Company’s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, pre-funded warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company’s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements relate to accrued research and development expense and valuation of equity-based instruments issued for other than cash. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </div>
CY2024Q2 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.667
CY2023Q2 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.6639
CY2024 bntc Average Foreign Exchange Rate For The Period
AverageForeignExchangeRateForThePeriod
0.6559
CY2023 bntc Average Foreign Exchange Rate For The Period
AverageForeignExchangeRateForThePeriod
0.673
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Concentrations of Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div>
CY2024 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
618987
CY2024 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35453286
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2456032
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21800000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19600000
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19400000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18000000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50900000
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5749152
CY2024Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.8
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2584239
CY2024Q2 bntc Class Of Warrant Purchase Price Per Warrant
ClassOfWarrantPurchasePricePerWarrant
4.7999
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2024Q2 bntc Gross Proceeds From Issuance Of Warrants
GrossProceedsFromIssuanceOfWarrants
40000000
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
75000
CY2024Q2 us-gaap Due From Banks
DueFromBanks
50866000
CY2023Q2 us-gaap Due From Banks
DueFromBanks
2477000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50929000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2490000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
577000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1280000
CY2024Q2 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2023Q2 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2024Q2 us-gaap Other Assets
OtherAssets
578000
CY2023Q2 us-gaap Other Assets
OtherAssets
1281000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
62000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
516000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1184000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1583000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1405000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1404000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1318000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
179000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87000
CY2024 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
87000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
136000
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1351000
CY2023Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1140000
CY2024Q2 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
0
CY2023Q2 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
109000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
97000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000
CY2024Q2 bntc Accrued Clinical Development Project Costs
AccruedClinicalDevelopmentProjectCosts
2504000
CY2023Q2 bntc Accrued Clinical Development Project Costs
AccruedClinicalDevelopmentProjectCosts
1750000
CY2024Q2 bntc Accrued Consultant Fees Current
AccruedConsultantFeesCurrent
75000
CY2023Q2 bntc Accrued Consultant Fees Current
AccruedConsultantFeesCurrent
88000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
138000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
69000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4165000
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3231000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
771000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
245000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
526000
CY2024 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
256000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
270000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
811000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
252000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
559000
CY2024 us-gaap Operating Lease Payments
OperatingLeasePayments
275000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
284000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
284000
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y11M15D
CY2024Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0467
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
291000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
291000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
284000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.22
CY2024 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
618987
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.9299
CY2023Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
27900000
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5749152
CY2024Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.8
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
34271146
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6300
CY2022Q2 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
178.5
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2348039
CY2023Q2 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
8.86
CY2023 bntc Class Of Warrants Excercisable And Outstanding
ClassOfWarrantsExcercisableAndOutstanding
2348039
CY2023 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable And Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisableAndOutstanding
8.86
CY2024 bntc Class Of Warrant Or Rights Issued During Period
ClassOfWarrantOrRightsIssuedDuringPeriod
16002175
CY2024 bntc Weighted Average Exercise Price Of Common Warrants Issued
WeightedAverageExercisePriceOfCommonWarrantsIssued
3.86
CY2024 bntc Class Of Warrants Excercisable And Outstanding
ClassOfWarrantsExcercisableAndOutstanding
34271146
CY2024 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable And Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisableAndOutstanding
1.8453
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.39
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.34
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.208
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.156
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0412
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0396
CY2024 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
830000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
452000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4243676000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
350000000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
34000
CY2021 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
34000
CY2022 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
34000
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21036000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-18953000
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-715000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-609000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21751000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2024Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14466000
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18388000
CY2024Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
172000
CY2023Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
221000
CY2024Q2 bntc Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
60000
CY2023Q2 bntc Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
117000
CY2024Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
264000
CY2023Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
263000
CY2024Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
218000
CY2023Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
234000
CY2024Q2 bntc Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
5771000
CY2023Q2 bntc Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
3070000
CY2024Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20951000
CY2023Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22293000
CY2024Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20594000
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21923000
CY2024Q2 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
57000
CY2023Q2 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
111000
CY2024Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
5000
CY2023Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
15000
CY2024Q2 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
99000
CY2023Q2 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
244000
CY2024Q2 us-gaap Deferred Tax Liabilities Unrealized Currency Transaction Gains
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
196000
CY2023Q2 us-gaap Deferred Tax Liabilities Unrealized Currency Transaction Gains
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
0
CY2024Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
357000
CY2023Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
370000
CY2024Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2024 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1329000
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024 bntc Effective Income Tax Reconciliation Percentage Permanent Differences
EffectiveIncomeTaxReconciliationPercentagePermanentDifferences
-0.0076
CY2023 bntc Effective Income Tax Reconciliation Percentage Permanent Differences
EffectiveIncomeTaxReconciliationPercentagePermanentDifferences
-0.0001
CY2024 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.008
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.0019
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0712
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2092
CY2024 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0003
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0012
CY2024 bntc Effective Income Tax Reconciliation On Tax Losses Upto Permissible Limit
EffectiveIncomeTaxReconciliationOnTaxLossesUptoPermissibleLimit
-0.2659
CY2023 bntc Effective Income Tax Reconciliation On Tax Losses Upto Permissible Limit
EffectiveIncomeTaxReconciliationOnTaxLossesUptoPermissibleLimit
0
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21751000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2024 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
619000
CY2023 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
0
CY2024 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22370000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19562000
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4060182
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4060182
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1385818
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1385818
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.51
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.51
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.12
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.12
CY2024 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
618987
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.05
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.05
CY2023Q3 bntc Percentage Variation Between Previously Reported And Currently Reported Earnings Per Share Diluted
PercentageVariationBetweenPreviouslyReportedAndCurrentlyReportedEarningsPerShareDiluted
-0.104
CY2023Q3 bntc Percentage Variation Between Previously Reported And Currently Reported Earnings Per Share Basic
PercentageVariationBetweenPreviouslyReportedAndCurrentlyReportedEarningsPerShareBasic
-0.104
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.65
bntc Percentage Variation Between Previously Reported And Currently Reported Earnings Per Share Diluted
PercentageVariationBetweenPreviouslyReportedAndCurrentlyReportedEarningsPerShareDiluted
-0.049
bntc Percentage Variation Between Previously Reported And Currently Reported Earnings Per Share Basic
PercentageVariationBetweenPreviouslyReportedAndCurrentlyReportedEarningsPerShareBasic
-0.049
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.21
bntc Percentage Variation Between Previously Reported And Currently Reported Earnings Per Share Diluted
PercentageVariationBetweenPreviouslyReportedAndCurrentlyReportedEarningsPerShareDiluted
-0.036
bntc Percentage Variation Between Previously Reported And Currently Reported Earnings Per Share Basic
PercentageVariationBetweenPreviouslyReportedAndCurrentlyReportedEarningsPerShareBasic
-0.036
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174462000
CY2023Q3 bntc Percentage Difference Between Previously Reported Accumulated Deficit And Restated Accumulated Deficit
PercentageDifferenceBetweenPreviouslyReportedAccumulatedDeficitAndRestatedAccumulatedDeficit
0.004
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-181260000
CY2023Q4 bntc Percentage Difference Between Previously Reported Accumulated Deficit And Restated Accumulated Deficit
PercentageDifferenceBetweenPreviouslyReportedAccumulatedDeficitAndRestatedAccumulatedDeficit
0.003
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-185539000
CY2024Q1 bntc Percentage Difference Between Previously Reported Accumulated Deficit And Restated Accumulated Deficit
PercentageDifferenceBetweenPreviouslyReportedAccumulatedDeficitAndRestatedAccumulatedDeficit
0.003
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
197550000
CY2023Q3 bntc Percentage Difference Between Previously Reported Additional Paid In Capital And Restated Additional Paid In Capital
PercentageDifferenceBetweenPreviouslyReportedAdditionalPaidInCapitalAndRestatedAdditionalPaidInCapital
0.003
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
197682000
CY2023Q4 bntc Percentage Difference Between Previously Reported Additional Paid In Capital And Restated Additional Paid In Capital
PercentageDifferenceBetweenPreviouslyReportedAdditionalPaidInCapitalAndRestatedAdditionalPaidInCapital
0.003
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
197874000
CY2024Q1 bntc Percentage Difference Between Previously Reported Additional Paid In Capital And Restated Additional Paid In Capital
PercentageDifferenceBetweenPreviouslyReportedAdditionalPaidInCapitalAndRestatedAdditionalPaidInCapital
0.003
CY2024 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001193125-24-226968-index-headers.html Edgar Link pending
0001193125-24-226968-index.html Edgar Link pending
0001193125-24-226968.txt Edgar Link pending
0001193125-24-226968-xbrl.zip Edgar Link pending
bntc-20240630.xsd Edgar Link pending
d640181d10k.htm Edgar Link pending
d640181dex191.htm Edgar Link pending
d640181dex211.htm Edgar Link pending
d640181dex231.htm Edgar Link pending
d640181dex311.htm Edgar Link pending
d640181dex312.htm Edgar Link pending
d640181dex321.htm Edgar Link pending
d640181dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g640181g01a19.jpg Edgar Link pending
g640181g01a20.jpg Edgar Link pending
g640181g01a21.jpg Edgar Link pending
g640181g01a22.jpg Edgar Link pending
g640181g01a23.jpg Edgar Link pending
g640181g01a24.jpg Edgar Link pending
g640181g02a19.jpg Edgar Link pending
g640181g03a19.jpg Edgar Link pending
g640181g09k54.jpg Edgar Link pending
g640181g09k56.jpg Edgar Link pending
bntc-20240630_cal.xml Edgar Link unprocessable
bntc-20240630_def.xml Edgar Link unprocessable
bntc-20240630_lab.xml Edgar Link unprocessable
bntc-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d640181d10k_htm.xml Edgar Link completed
g640181g09k57.jpg Edgar Link pending
g640181g09k59.jpg Edgar Link pending
g640181g09k60.jpg Edgar Link pending
g640181g09k61.jpg Edgar Link pending
g640181g12j10.jpg Edgar Link pending
g640181g25a01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending